Lexeo Therapeutics, Inc. completed its acquisition of Mantle Therapeutics Inc. on 2026-09-29, according to the Form 8-K Lexeo Therapeutics, Inc. filed with the SEC on 2026-09-29. The filing's Item 2.01 states no aggregate dollar price.
| Acquirer | Lexeo Therapeutics, Inc. |
|---|---|
| Acquired | Mantle Therapeutics Inc. |
| Completed | 2026-09-29 |
| Reported by | Lexeo Therapeutics, Inc. (LXEO), the buyer |
| Filing | Form 8-K, filed 2026-09-29 |
Want the whole picture on Lexeo Therapeutics, Inc.?
Example from a real report (our sample on Target): “The Q2 2026 earnings report, published August 19, 2026, showed adjusted EPS of $2.46 against an expected $2.33” Source: CNBC
A Full Report on Lexeo Therapeutics, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Lexeo Therapeutics, Inc. covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
1 cited source found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
What the filing says
On September 29, 2026, Lexeo Therapeutics, Inc. (" Lexeo " or the " Company ") completed the previously announced acquisition of Mantle Therapeutics Inc. (" Mantle "), pursuant to the Agreement and Plan of Merger dated September 16, 2026 (the " Merger Agreement ") by and among the Company, Mantle and Magma Merger Sub Inc., a Delaware corporation and a wholly-owned subsidiary of the Company (" Merger Sub "), and Shareholder Representative Services LLC, a Colorado limited liability company, solely in its capacity as representative, agent and attorney in fact of the Sellers.
More from the filing
Pursuant to the Merger Agreement, Merger Sub was merged with and into Mantle (the " Merger "), with Mantle continuing as the surviving corporation and wholly owned subsidiary of Lexeo.
The shares of Common Stock issued in connection with the Merger were not registered under the Securities Act of 1933, or any applicable state securities laws and were issued in reliance on the exemption from registration provided by Section 4(a)(2) of the Securities Act and/or Regulation D promulgated thereunder.
New risks and uncertainties may emerge from time to time, and it is not possible to predict all risks and uncertainties.
Quoted from Lexeo Therapeutics, Inc.'s Form 8-K.
This is the only completed acquisition Lexeo Therapeutics, Inc. reported under Item 2.01 in the last twelve months.
Who runs it now, who owns it, where the money comes from and what to watch for, every claim linked to its source.
Order Full Report on Lexeo Therapeutics, Inc.Look up Lexeo Therapeutics, Inc. and see what is on record before you decide.
Get the free SnapshotWhere this comes from
A public company must file a current report on Form 8-K with the SEC within four business days of completing a significant acquisition or disposition of assets, under Item 2.01 of the report. The acquired company sometimes files one too, when the deal makes it a subsidiary of the buyer.
Every fact on this page is taken from one of those filings and linked to it: which company acquired which, the date the filing gives for completion, and the price when the filing states one in dollars, shown next to the sentence that states it. A filing states what was bought and on what terms; it rarely states why, and neither does this page.